Similarly, re-analysis of the E-GEOD-13070 clinical cohort on human IR and thiazolidinedione (TZD)-mediated insulin sensitization (IS) (n = 11 samples, 54,675 genes) (https://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-13070/) demonstrated enhanced co-expression of IR and PD biomarkers in IR subjects, converse to their low expression in the IS group (Figure S1). This evidence concerns the gene INS and Parkinson disease.